In this enlightening conversation, Gilad Almogy, CEO of Ultima Genomics and a semiconductor expert, shares insights into how his company is revolutionizing DNA sequencing. By driving costs down from $1,000 to just $80 per genome, Ultima is opening doors for applications in cancer diagnostics and personalized medicine. The discussion emphasizes the role of AI in biology, the transformative impact of affordable sequencing, and the potential for real-time cancer detection. Almogy’s vision includes achieving a remarkable $10 genome, paving the way for groundbreaking innovations in healthcare.
